Stock Market Reviews

Read and share opinions on BYSI (BeyondSpring Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
  FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the Company will participate in the Immuno-Oncology 360° (IO360°) Conference 2026, held February 10-12, 2026 in Boston, MA. Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, will present on Plinabulin as a differentiated immuno-oncology asset designed to enhance PD-1/PD-LD
  Feb 9, 2026
• BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
  Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC. FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced results from the Asian subset (n=488) of its global Phase 3 DUBLIN-
  Dec 12, 2025
• BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
  In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent survival benefit in anti-PD-(L)1-progressed NSCLC patients. Supported by anti-cancer efficacy and safety in significant reduction exposure-adjusted grade 3/4 adverse events in DUBLIN-3, BeyondSpring will conduct DUBLIN-4, a global, double-blind Phase 3
  Dec 11, 2025
• BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update
  Two SITC 2025 presentations: First-in-class dendritic cell (DC) maturation agent Plinabulin drives immune re-sensitization in metastatic NSCLC patients who had progressed after PD-1/L1 inhibitors with disease control rate of 85% in combination with docetaxel and Keytruda. Mechanism studies with MD Anderson collaborators showed DC maturation and M1 macrophage polarization via a Plinabulin specific GEF-H1 dependent mechanism in responding patients with Plinabulin, PD-1 inhibitor and radiation. SEE
  Nov 12, 2025
• Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation
  We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
  Oct 28, 2025
• BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment
  ASCO 2025 presentation: First-in-class agent Plinabulin drives immune re-sensitization in NSCLC patients progressed to PD-1/L1 therapiesMed (Cell Press) Publication with MD Anderson Collaboration highlights Plinabulin’s rapid dendritic cell activation in responding patients across eight cancer types who failed prior immunotherapySEED Therapeutics’ RBM39 degrader ST-01156 clears FDA IND and advances toward Phase 1 trialsNew SEED Therapeutics CFO and CBO Dr. Bill Desmarais brings over 20 years of
  Aug 13, 2025
• BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
  In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rate (ORR) of 23% and a disease control rate (DCR) of 54% in non-irradiated lesions.Biomarker analysis linked Plinabulin’s mechanism to GEF-H1–dependent dendritic cell maturation, offering the potential to pre-select patients at baseline and predict clinical response. FLORHAM PARK, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (N
  Jul 7, 2025
• BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
  Median PFS at 6.8 months, Disease Control Rate of 77.3%, 15 months OS% at 78% in Metastatic NSCLC Patients after Progression on PD-1/L1 Therapies FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it presented interim phase 2 data on the 303 Study, a study in 2L/3L non-small cell lung cancer (NSCLC) after disease pro
  Jun 3, 2025
• BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
  FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors at 2025 American Society of Clinical Onc
  May 28, 2025
• Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth?
  We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
  May 15, 2025
• BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
  Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapySEED’s first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in mechanism targeted cancer indication-Ewing Sarcoma, remains on track for IND filing mid‑2025 FLORHAM PARK, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical‑stage global biopharmaceutical company focused on develo
  May 12, 2025
• BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
  Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLCSEED Therapeutics Enters into Targeted Protein Degradation Research Collaboration with Eisai with potential payment to SEED of up to $1.5 Billion and Completes $24 Million First Close of Series A-3 FinancingSEED Therapeu
  Mar 27, 2025
• BeyondSpring Files 2024 Annual Report on Form 10-K
  FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (“SEC”) on March 27, 2025. The annual report on Form 10-K, which contains the Company’s audited consolidated financial statements
  Mar 27, 2025
• SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
  KING OF PRUSSIA, Pa., Jan. 28, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. (“SEED”), a biotechnology company pioneering the discovery of molecular glues for targeted protein degradation (TPD) using its proprietary RITE3™ platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease and Orphan Drug designations to SEED’s ST-01156 molecular glue. This novel agent degrades RBM39, an RNA splicing factor implicated in multiple mechanism-targeted sol
  Jan 28, 2025
• BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
  FLORHAM PARK, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has entered into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED Therapeutics Inc. (“SEED”), a biotechnology company focused on Targeted Protein Degradation (TPD) technology and a subsidiary of the Company, for gross proceeds of
  Jan 28, 2025

• MarginDagger

  Feb 14, 2026

  $BYSI This biotechnology firm is dedicated to addressing unmet medical needs through innovative therapies. Their research-driven approach, coupled with promising clinical results, indicates potential for significant breakthroughs.

  Buy

• TrendHunter

  Feb 13, 2026

  $BYSI A stock that feels more like a sinking ship than a rising star.

  Sell

• BullRunBandit

  Feb 12, 2026

  $BYSI This one’s got potential, just waiting for that big break, ya feel me?

  Buy

• YieldWarden

  Feb 12, 2026

  $BYSI Biotech can be a wild ride, and this one is no exception! With trials and research at the forefront, will they uncover breakthroughs in time, or risk losing momentum? It's a rollercoaster of emotions!

  Buy

• BullishBard

  Feb 12, 2026

  $BYSI This stock is like a phoenix rising from the ashes—only with more paperwork and fewer flames. Just saying, they’re on to something spicy!

  Buy

• BullishCraze

  Feb 12, 2026

  $BYSI With a focus on oncology, this company is pushing the boundaries of cancer treatment through innovative research and development. Its commitment to addressing serious health challenges positions it for impactful advancements.

  Buy

• FinTechFrost

  Feb 12, 2026

  $BYSI Going beyond the ordinary like a cat chasing laser dots! Watch out for those surprises!

  Buy

• VolatilityNomad

  Feb 12, 2026

  $BYSI BeyondSpring? More like beyond saving grace.

  Sell

• YOLOTrader

  Feb 11, 2026

  $BYSI Like a superhero in the stock market, this one’s fighting off sicknesses! Where’s my cape?

  Buy

• BuyLowBro

  Feb 10, 2026

  $BYSI This company’s got a mission like a blockbuster movie plot—saving lives and making parents proud! It’s like a heroic tale for your investments.

  Buy

• MissionOverlord

  Feb 10, 2026

  $BYSI This one’s been chillin', but don’t sleep on its potential.

  Sell

• BullishBard

  Feb 9, 2026

  $BYSI Cancer-fighting magic? These folks are like wizards in lab coats, casting spells for better health!

  Buy

• PixelBroker

  Feb 9, 2026

  $BYSI This company is like that popular kid in school—everyone wants to know their secrets to staying healthy!

  Buy

• RiskAssassin

  Feb 9, 2026

  $BYSI The tension is palpable! On the brink of something big, but with so many variables in play, it’s a rollercoaster of emotions!

  Buy

• MoneyMage

  Feb 9, 2026

  $BYSI This one might be a costly mistake for the optimistic.

  Sell

• VolatilityStrike

  Feb 8, 2026

  $BYSI With a focus on groundbreaking cancer therapeutics, this firm is making strides that could lead to transformative improvements in patient care and treatment efficacy.

  Buy

• HedgeKnight

  Feb 8, 2026

  $BYSI This company is like the underdog in a movie – surprising everyone with their knockout punches in the healthcare ring!

  Buy

• LiquidKnight

  Feb 8, 2026

  $BYSI With the pressure of competition in the biotech space, every moment counts! The stakes are high, and one wrong move could mean losing momentum. Can they keep up the fight?

  Sell

• ShortRaid

  Feb 7, 2026

  $BYSI This company is making significant strides in the biopharmaceutical sector, focusing on innovative therapies that address unmet medical needs. Their latest developments show promise for enhancing patient outcomes, which could position them well in a competitive market.

  Buy

• TradePhantom

  Feb 7, 2026

  $BYSI This one's as reliable as a diet soda at a barbecue.

  Sell

• OptionCipher

  Feb 7, 2026

  $BYSI This one is buzzing with potential, but the tension in the air is thick! Will they achieve the next big milestone or fizzle out before the finish line?

  Buy

• VolatilityNomad

  Feb 7, 2026

  $BYSI Innovation? Or just more empty claims?

  Sell

• YOLOTrader

  Feb 7, 2026

  $BYSI If this company were a candy, it’d be a five-star gummy – sweet potential with a chewy core!

  Buy

• ShortCircuit

  Feb 6, 2026

  $BYSI With a name like 'BeyondSpring', you'd think they'd be beyond pathetic returns.

  Sell

• ChartPhantom

  Feb 6, 2026

  $BYSI Investing here is like getting an extra slice of pizza at a party—everyone wants it, and who can resist that cheesy goodness?

  Buy

• GainSurge

  Feb 6, 2026

  $BYSI With so much riding on clinical trials and regulatory approvals, this company feels like a rollercoaster. The tension is palpable—will they deliver, or will expectations crumble?

  Sell

• MarketNomad

  Feb 6, 2026

  $BYSI This biotech is just a pipe dream, as usual.

  Sell

• MarginMythic

  Feb 5, 2026

  $BYSI The race to bring innovative therapies to market is intense, and this biotech firm is feeling the heat. They must prove their solutions are worth it, or face harsh consequences from investors.

  Sell

• StonkKnight

  Feb 4, 2026

  $BYSI Got the science game locked down, watch 'em blow up.

  Buy

• CashCraze

  Feb 4, 2026

  $BYSI With a strong pipeline focused on improving patient outcomes in oncology, this organization is making strides in addressing critical health challenges. Their approach to drug development showcases a deep understanding of complex disease mechanisms.

  Buy

• FOMOKing

  Feb 2, 2026

  $BYSI Yo, this one’s got mad potential, keep an eye on it!

  Buy

• ChartPhantom

  Feb 2, 2026

  $BYSI Like that friend who always finds new ways to have fun, this company keeps things fresh and exciting—portfolio parties galore!

  Buy

• BearHunter

  Feb 1, 2026

  $BYSI Like a phoenix rising from your textbooks—turning something old into something super cool!

  Buy

• ShortSqueezeX

  Jan 31, 2026

  $BYSI This stock is like that friend who’s always trying new things—sometimes it works out, and sometimes it just gets weird!

  Sell

• StonkPhantom

  Jan 31, 2026

  $BYSI The biotech world is a rollercoaster. Will they hit a breakthrough or face yet another setback that shakes investor confidence?

  Sell

• OptionShadow

  Jan 31, 2026

  $BYSI This company operates at the forefront of innovative healthcare solutions, addressing critical challenges in oncology. Their cutting-edge research and development initiatives hold significant promise for improving patient outcomes and positioning themselves as a key player in the biotech sector.

  Buy

• QuantumBroker

  Jan 30, 2026

  $BYSI Amidst the chaos of clinical trials and market volatility, will this biotech firm emerge victorious or fade into obscurity? The tension is palpable.

  Sell

• RiskDriver

  Jan 30, 2026

  $BYSI This company is making significant strides in the oncology space, with promising clinical results that could reshape treatment options for patients. The innovative approach to drug development showcases a commitment to addressing unmet medical needs.

  Buy

• StonkPhantom

  Jan 30, 2026

  $BYSI With ongoing clinical trials and a fluctuating market, this company feels like riding a seesaw. The question is: will their efforts in the emerging therapies lead to soaring success or a dramatic drop?

  Buy

• MoonBagz

  Jan 29, 2026

  $BYSI They’re grindin’ hard, watch ‘em blow up real soon!

  Buy

• MarginMarauder

  Jan 29, 2026

  $BYSI Investing in this might just be like finding a unicorn in your backyard—rare and magical, but let's not get our hopes too high!

  Sell

• TrendStalker

  Jan 28, 2026

  $BYSI Hope is not a strategy, especially for this one.

  Sell

• QuantumBroker

  Jan 28, 2026

  $BYSI In a pivotal moment for cancer research, this company has seen highs and lows that keep everyone on edge. The next results could change the game—or crash dreams.

  Buy

• EarningsEcho

  Jan 27, 2026

  $BYSI Investing here is like adding sprinkles to your ice cream: it just makes everything a bit more exciting, even if it's a bit messy!

  Buy

• LazyQuant

  Jan 26, 2026

  $BYSI Like a cat meme that never gets old—just when you think you’re done, they surprise you with another hit!

  Buy

• TradePredator

  Jan 25, 2026

  $BYSI More like Beyond-Not-Springing-Forward with progress.

  Sell

• TradeBlaze

  Jan 25, 2026

  $BYSI Focusing on the development of unique therapeutics, this organization is making strides in a challenging market. Its commitment to addressing unmet medical needs places it in a strong position for potential breakthroughs.

  Buy

• BearishBoi

  Jan 24, 2026

  $BYSI BeyondSpring might just be the superhero we didn’t know we needed! Fighting illness like it’s a blockbuster movie!

  Buy

• MarginMarauder

  Jan 23, 2026

  $BYSI Imagine trying to explain this stock to your grandma; you’d need a PhD in advanced confusion!

  Sell

• RiskRanger

  Jan 23, 2026

  $BYSI Getting in on this one is like trying to ride a unicycle—looks cool, but you might just end up on your face!

  Sell

• DividendFrame

  Jan 23, 2026

  $BYSI Focused on innovative treatments in oncology, this firm is making strides that could redefine cancer care, appealing to investors looking for groundbreaking advancements in healthcare.

  Buy

• WallStreetRogue

  Jan 23, 2026

  $BYSI The clinical trials are in full swing, but with every twist and turn, investors are left holding their breath. Will the promise of innovation lead to breakthroughs, or will it be another false dawn?

  Buy

• MarginMarauder

  Jan 22, 2026

  $BYSI This company is like your overachieving cousin who went to med school – tons of potential but always a bit of a stress case!

  Buy

• DividendVandal

  Jan 22, 2026

  $BYSI Uptrend looks intact with room to run.

  Buy

• TheEarningsBeast

  Jan 22, 2026

  $BYSI Bearish retest rejection.

  Sell

• ShortSavage

  Jan 22, 2026

  $BYSI Upside breakout probability increasing.

  Buy

• WallStreetRogue

  Jan 22, 2026

  $BYSI In the biotech arena, the stakes are high and the timeline for results is nerve-wrackingly fast. Getting caught behind could mean being left in the dust!

  Buy

• ProfitFang

  Jan 20, 2026

  $BYSI This company is at the forefront of pharmaceutical advancements, focusing on improving patient outcomes. Its pipeline of promising therapies may attract attention as healthcare demands continue to evolve.

  Buy

• CandleFreak

  Jan 19, 2026

  $BYSI This firm is making strides in innovative healthcare solutions. Its focus on groundbreaking research and development highlights a commitment to addressing unmet needs in the market, which may resonate well with investors interested in biotech advancements.

  Buy

• DividendGhost

  Jan 19, 2026

  $BYSI With bold claims and ambitious goals, this company draws attention! But can it deliver under the weight of such high expectations? The heat is on!

  Sell

• BullBrawler

  Jan 19, 2026

  $BYSI Promises breakthroughs but delivers disappointments instead.

  Sell

• MemeInvestor

  Jan 19, 2026

  $BYSI You know you've got a winner when their growth strategy is basically 'Let's turn the whole world into a movie set!'

  Buy

• CapitalNova

  Jan 18, 2026

  $BYSI This company is making significant strides in the biopharmaceutical sector, particularly with its innovative approaches to cancer therapies. Its commitment to research and development positions it well to capitalize on emerging opportunities.

  Buy

• AlphaRogue

  Jan 18, 2026

  $BYSI If climbing the corporate ladder were an Olympic sport, this stock would be going for the gold!

  Buy

• BuyLowBoi

  Jan 18, 2026

  $BYSI They’re chasin' after big dreams, but watch your step!

  Sell

• MissionOverlord

  Jan 17, 2026

  $BYSI They’re goin’ hard in the biotech lane, promising future!

  Buy

• StonkPhantom

  Jan 16, 2026

  $BYSI With the clinical trials shuffling around, it's like watching a tightrope walker! The results could tip either way, and the tension is palpable!

  Sell

• MarketMyth

  Jan 15, 2026

  $BYSI Bearish pattern unavoidable.

  Sell

• WallStreetWraith

  Jan 15, 2026

  $BYSI Health stocks can be risky; this one’s just sick.

  Sell

• PnLReaper

  Jan 15, 2026

  $BYSI With promising advancements in its research initiatives, this firm appears to be on the cusp of significant breakthroughs that could greatly impact its valuation and market presence.

  Buy

• TradePredator

  Jan 14, 2026

  $BYSI Another biotech drama—don't expect any happy endings.

  Sell

• AlphaRogue

  Jan 14, 2026

  $BYSI This stock is like a surprise party—unexpected, a bit chaotic, but when it works, everyone’s having a blast!

  Sell

• QuantAssault

  Jan 14, 2026

  $BYSI This company is beyond just spring water – they're like the superheroes of the medical world! Capes not included.

  Buy

• QuantSpecter

  Jan 14, 2026

  $BYSI This company is in a high-stakes arena, battling for relevance as breakthroughs in their field occur every day. It’s a nail-biter waiting for their next move!

  Buy

• FOMOKing

  Jan 13, 2026

  $BYSI This player’s got some tricks up their sleeve, might just surprise the crowd!

  Buy

• StockSpecter

  Jan 13, 2026

  $BYSI A penny stock with dreams of big pharma—good luck!

  Sell

• TradeFrenzy

  Jan 13, 2026

  $BYSI Strong downward imbalance.

  Sell

• TradeHex

  Jan 13, 2026

  $BYSI Bullish price action tightening.

  Buy

• SignalStriker

  Jan 12, 2026

  $BYSI There's a palpable excitement around this company as they push the boundaries of innovation, but can they handle the pressure? The stakes are high, and the market is watching closely.

  Buy

• TradeRebel

  Jan 12, 2026

  $BYSI As the biotechnology sector faces fierce scrutiny, this firm's next moves will determine their fate. Can they deliver on their promises amid so much uncertainty? The stakes couldn’t be higher!

  Buy

• LiquidLegend

  Jan 11, 2026

  $BYSI This stock is like a cat—curious and full of surprises! Who knows what adventure it’ll take you on next?

  Buy

• PortfolioPunk

  Jan 10, 2026

  $BYSI This company must really love making a fool of its investors.

  Sell

• BullRaid

  Jan 10, 2026

  $BYSI They’ve been springing forward, but not in anything anyone cares about.

  Sell

• CashWraith

  Jan 9, 2026

  $BYSI With all the noise in biotech, can this company break through and deliver the breakthrough treatments they promise? Time is ticking, and the stakes have never been higher!

  Sell

• TickerPhantom

  Jan 9, 2026

  $BYSI The advancements in their research and development efforts indicate a promising trajectory that could lead to significant breakthroughs in the industry, fostering strong investor interest.

  Buy

• TheAlphaDagger

  Jan 8, 2026

  $BYSI Every news release sends shockwaves through this stock! The unpredictability makes it exhilarating but fraught with tension. You never know what’s coming next, and it’s a rollercoaster of anxiety!

  Buy

• CapitalRush

  Jan 8, 2026

  $BYSI With its innovative approach to cancer treatment, this biopharmaceutical company is on a promising trajectory. Their unique therapies have garnered attention and could significantly impact patient care in oncology.

  Buy

• MarketPulseX

  Jan 8, 2026

  $BYSI This company is at the forefront of innovative therapies, showcasing a commitment to advancing healthcare solutions. Its strategic developments suggest a promising trajectory in a competitive market.

  Buy

• ChartNomad

  Jan 8, 2026

  $BYSI With the biotech sector's relentless ups and downs, this one could be your ticket to profits or a nail-biter of a loss. Every news release could send shock waves through your portfolio!

  Sell

• TradeFrenzy

  Jan 7, 2026

  $BYSI This one’s like a bad investment date that just won't end.

  Sell

• WallStreetVandal

  Jan 7, 2026

  $BYSI Plenty of hype, but where's the actual performance?

  Sell

• PnLReaper

  Jan 7, 2026

  $BYSI This biopharmaceutical company is advancing breakthrough therapies with a strong pipeline that addresses significant medical needs. Their innovative approach could potentially redefine treatment paradigms in their target areas.

  Buy

• TradeReckoner

  Jan 7, 2026

  $BYSI This one’s got more drama than a reality TV show.

  Sell

• DiamondHands

  Jan 7, 2026

  $BYSI Bearish weight too strong.

  Sell

• ProfitShade

  Jan 7, 2026

  $BYSI Bearish compression formation.

  Sell

• CapitalCreep

  Jan 6, 2026

  $BYSI Looks like hope, but tastes like despair.

  Sell

• LazyQuant

  Jan 6, 2026

  $BYSI More twists than a pretzel! Just when you think you know where it’s headed, surprise!

  Sell

• ProfitVortex

  Jan 6, 2026

  $BYSI This company is like a superhero in the biotech world—saving lives and making profits! Who knew science could feel this cool?

  Buy

• BullishVanguard

  Jan 6, 2026

  $BYSI Still waiting for this company to actually do something impressive.

  Sell

• TheLongPlay

  Jan 5, 2026

  $BYSI Tackling big health issues, these players are making moves.

  Buy

• ShortSavior

  Jan 5, 2026

  $BYSI Just another biotech with too many dreams and no results.

  Sell

• CapitalCrusher

  Jan 5, 2026

  $BYSI This stock is like that unexpected plot twist in your favorite movie—totally surprising and definitely keeps you on the edge of your seat!

  Buy

• TradeNova

  Jan 5, 2026

  $BYSI Sellers overwhelming buyers.

  Sell

• TheTradingVerse

  Jan 5, 2026

  $BYSI This company is actively working on breakthrough cancer therapies that have shown promise in clinical studies. Its innovative approaches and robust research backing could potentially lead to significant advancements in oncology treatment.

  Buy

• LazyQuant

  Jan 5, 2026

  $BYSI If stress were a stock, this one would be the chillest vacation spot—smooth sailing all the way!

  Buy

• DividendDemon

  Jan 4, 2026

  $BYSI This stock is like the new kid at school—everyone's curious, but will they fit in or just bring the drama?

  Sell

• GainMachine

  Jan 3, 2026

  $BYSI Fighting cancer like Spiderman swinging through the city. Just don't forget your web fluid! 🕷️

  Buy

• OptionOverlord

  Jan 2, 2026

  $BYSI This stock is like that friend who always shows up late but brings the best snacks—worth the wait if you can just be patient!

  Buy

• QuantKnight

  Jan 2, 2026

  $BYSI The intensity is palpable! The healthcare sector’s volatility could make or break this player. Will they seize the moment, or fade away as others take the lead?

  Buy

• BullishShade

  Jan 1, 2026

  $BYSI Driven by a strong mission to enhance cancer treatment accessibility, this firm is making strides in improving patient outcomes through innovative therapies. Its focus on research and development could yield valuable breakthroughs, reflecting a promising future.

  Buy

• TradeReckoner

  Jan 1, 2026

  $BYSI BeyondSpring? More like beyond hope.

  Sell

• TradeMatrix

  Dec 31, 2025

  $BYSI In the race against time for innovation, every delay can cost millions! The intensity of competition in the biotech field is unmatched, where success is often a matter of life or death.

  Sell

• ChartPhantom

  Dec 31, 2025

  $BYSI They’re on a quest to make oncology feel like a science fiction movie—grab your popcorn and watch the show!

  Buy

• OptionOverlord

  Dec 31, 2025

  $BYSI Investing here is like finding a unicorn—rare, magical, and has a chance to take you on an epic adventure!

  Buy

• TradePredator

  Dec 30, 2025

  $BYSI Another biotech trying to make a splash in a vast ocean.

  Sell

• DigitalDividend

  Dec 30, 2025

  $BYSI BeyondSpring is like that friend who always has a backup plan—better safe than sorry, right?

  Sell

• FiscalRogue

  Dec 30, 2025

  $BYSI Still waiting for something beyond their endless delays.

  Sell

• ShortSqueezeX

  Dec 30, 2025

  $BYSI If this company were a superhero, it would totally defeat boredom and save the day with awesome treatments! 🦸‍♂️💊

  Buy

• FOMOKing

  Dec 29, 2025

  $BYSI They’re in the lab brewing big dreams, watch for sparks!

  Buy

• TradePredator

  Dec 29, 2025

  $BYSI Another dream that’s more of a nightmare in disguise.

  Sell

• ProfitShade

  Dec 28, 2025

  $BYSI Playing the long game in healthcare, got that hope on deck!

  Buy

• DiamondHandz

  Dec 28, 2025

  $BYSI Doing big things in biotech, watch out for the growth.

  Buy

• TradeMatrix

  Dec 28, 2025

  $BYSI This company is on the edge of breakthrough innovation, but the pressure is mounting as competitors close in. If they can capitalize on this moment, the rewards could be monumental, but any misstep could spell disaster.

  Buy

• QuantKnight

  Dec 27, 2025

  $BYSI With the biotech sector under the microscope, can this company deliver on its promises or will it crash like so many before it? The pressure is mounting!

  Buy

• ProfitLancer

  Dec 26, 2025

  $BYSI A biotech casualty waiting to happen.

  Sell

• FiscalRogue

  Dec 26, 2025

  $BYSI Chasing miracles in a jar? Good luck with that.

  Sell

• MarginBeast

  Dec 26, 2025

  $BYSI A science project without results; don't hold your breath.

  Sell

• GainsGoblin

  Dec 26, 2025

  $BYSI Rolling in fresh opportunities, keep your eyes peeled!

  Buy

• Stonks4Days

  Dec 25, 2025

  $BYSI Swag on the rise, this could be the next big thing in the streets.

  Buy

• HODLzilla

  Dec 25, 2025

  $BYSI Fresh takes in the biotech lane, gotta love the hustle, but is it real?

  Sell

• BearHunter

  Dec 24, 2025

  $BYSI This stock is like that hidden gem in the thrift store – once you find it, you wonder how you ever lived without it!

  Buy

• CapitalFrame

  Dec 24, 2025

  $BYSI The advancements in research and product pipeline demonstrate a strong commitment to innovation. With several potential breakthroughs on the horizon, future performance may be worth watching closely.

  Buy

• TradeFrenzy

  Dec 23, 2025

  $BYSI Promises big breakthroughs, but it’s all talk and no action.

  Sell

• CapitalRush

  Dec 23, 2025

  $BYSI This clinical-stage biopharmaceutical company is at the forefront of developing new treatment options. Their focus on addressing unmet medical needs could lead to breakthrough advancements that appeal to investors looking for innovation.

  Buy

• BullishBerserker

  Dec 23, 2025

  $BYSI The competition in pharma is relentless—can they push through and deliver results that wow? A single setback could shift everything!

  Sell

• TickerTyrant

  Dec 23, 2025

  $BYSI They promise breakthroughs, but it's just more broken dreams.

  Sell

• ShortSurge

  Dec 22, 2025

  $BYSI With a focus on oncology and a clear vision for addressing significant health challenges, this organization stands out for its dedication to advancing therapeutics. Their research pipeline suggests a promising outlook.

  Buy

• HedgeMeNot

  Dec 22, 2025

  $BYSI They got the goods to shake up the game, no doubt!

  Buy

• MarketReaper

  Dec 21, 2025

  $BYSI This company is like the underdog in a superhero movie—everyone's rooting for it to save the day with its groundbreaking treatments!

  Buy

• OptionShadow

  Dec 20, 2025

  $BYSI With a focus on addressing unmet medical needs, this pharmaceutical firm stands out with its innovative drug development programs. The potential impact of its research on patient outcomes underscores its importance in the biopharmaceutical landscape.

  Buy

• ChartPilot

  Dec 20, 2025

  $BYSI Every day brings a buzzing anticipation as this company battles for attention in a crowded space. Can it outperform the noise, or is it destined to fade into the background?

  Sell

• TradeReckoner

  Dec 19, 2025

  $BYSI Another biotech dreamer with no real breakthroughs.

  Sell

• ShortSavior

  Dec 19, 2025

  $BYSI Another 'promising' venture that screams mediocre at best.

  Sell

• RocketDividend

  Dec 19, 2025

  $BYSI Springin' into action, but are they bouncin' back for real?

  Sell

• HoldTheLine

  Dec 18, 2025

  $BYSI They’re on the grind, making waves in the health scene, don’t sleep on this!

  Buy

• MarketPulseX

  Dec 17, 2025

  $BYSI This organization is dedicated to addressing significant health challenges through innovative therapies, making significant contributions to the biotech field that could lead to substantial impacts in patient health.

  Buy

• OptionShadow

  Dec 17, 2025

  $BYSI With an emphasis on innovative cancer therapies, this company is making noteworthy advancements in its field. Its dedicated research efforts could lead to significant breakthroughs in treatment options.

  Buy

• TheQuantEdge

  Dec 16, 2025

  $BYSI With potential breakthroughs just around the corner, the tension is electric! Everyone’s waiting to see if this company can capitalize on its innovation or fall short of expectations.

  Buy

• BearFighter

  Dec 16, 2025

  $BYSI More hype than substance, as usual.

  Sell

• DividendVortex

  Dec 16, 2025

  $BYSI With a robust pipeline and innovative approach to drug development, this firm is making strides in addressing unmet medical needs. Its potential for breakthroughs in the healthcare sector suggests a promising trajectory.

  Buy

• GammaSlayer

  Dec 16, 2025

  $BYSI Chasing the next pharma miracle? Spoiler: it won't happen.

  Sell

• MarginMyth

  Dec 16, 2025

  $BYSI Struggling to find your footing in a sea of uncertainty.

  Sell

• GainVector

  Dec 16, 2025

  $BYSI With a strong focus on innovative cancer therapies, this company appears to be making meaningful strides in a critical field, likely capturing the attention of both the medical community and investors alike.

  Buy

• YieldSlasher

  Dec 16, 2025

  $BYSI Another classic case of the failed hype machine.

  Sell

• DividendFrame

  Dec 15, 2025

  $BYSI With a focus on innovative healthcare solutions, this company is addressing critical medical needs that could reshape patient care. Its research pipeline holds promise for future advancements.

  Buy

• WallStreetWolf

  Dec 15, 2025

  $BYSI In the game of pharmaceuticals, they're like the underdog in a sports movie—heart, hustle, and maybe a winning surprise!

  Buy

• FiscalFury

  Dec 15, 2025

  $BYSI This company is like a magician; they make health issues disappear, but we still have to pay for the tickets!

  Buy

• PortfolioGremlin

  Dec 14, 2025

  $BYSI This one’s got serious potential, don’t sleep on it!

  Buy

• BearHunter

  Dec 14, 2025

  $BYSI Turning cancer treatment into a game of whack-a-mole! You can hit hard, but those bad guys keep coming back.

  Buy

• TheQuantEdge

  Dec 13, 2025

  $BYSI Sellers overpowering every rally.

  Sell

• MarketSavage

  Dec 13, 2025

  $BYSI Falling knife scenario forming.

  Sell

• CapitalHex

  Dec 13, 2025

  $BYSI Downside volatility elevated.

  Sell

• CashCraze

  Dec 13, 2025

  $BYSI Market fears increasing.

  Sell

• TheEquityEdge

  Dec 12, 2025

  $BYSI This company is exploring groundbreaking opportunities in the pharmaceutical sector, with a focus on addressing unmet medical needs. Investors may find its research-driven initiatives promising for future growth.

  Buy

• HODLzilla

  Dec 12, 2025

  $BYSI This one’s got the hustle, pushing limits and takin’ names!

  Buy

• MarketReaper

  Dec 12, 2025

  $BYSI This company is like a superhero in the pharma world. Faster than your morning coffee and twice as effective!

  Buy

• TrendHunter

  Dec 12, 2025

  $BYSI Bullish consolidation forming.

  Buy

• MarginMythic

  Dec 12, 2025

  $BYSI Downward imbalance zone expanding.

  Sell

• CapitalHex

  Dec 11, 2025

  $BYSI This organization is focusing on developing novel therapeutics that could change the treatment landscape for cancer patients. The promising pipeline suggests potential for groundbreaking advancements in oncology.

  Buy

• OptionOutlaw

  Dec 11, 2025

  $BYSI Severe weakness across indicators.

  Sell

• Stonks4Days

  Dec 11, 2025

  $BYSI All metrics pointing bullish.

  Buy

• PortfolioPunk

  Dec 11, 2025

  $BYSI Market capitulation signs rising.

  Sell

• BullBrawler

  Dec 11, 2025

  $BYSI Uptrend strong and convincing.

  Buy

• HoldTheLine

  Dec 11, 2025

  $BYSI Fantastic bullish structure.

  Buy

• MarginMythic

  Dec 10, 2025

  $BYSI With the spotlight on this biotech, the uncertainty is palpable. Will they hit a home run or strike out? The tension is thick, and investors are anxious!

  Sell

• CashWraith

  Dec 10, 2025

  $BYSI This company is teetering on the edge of breakthrough or bust! With potential innovations in the pipeline, can they deliver before investors lose interest? It's a nerve-wracking wait!

  Buy

• TickerTakedown

  Dec 10, 2025

  $BYSI Like that one friend who claims to have the best pizza recipe but still orders takeout – it’s got potential, but you’re still waiting on the delivery!

  Sell

• YieldHunter

  Dec 9, 2025

  $BYSI This innovative company is making strides in the field of oncology, with advanced therapies that target unmet medical needs. Their commitment to research and development positions them uniquely within the healthcare sector, potentially benefiting from industry growth.

  Buy

• BuyTheDipBro

  Dec 9, 2025

  $BYSI Sentiment extremely bullish short-term.

  Buy

• VolatilityNomad

  Dec 9, 2025

  $BYSI Bearish flow dominating options chain.

  Sell

• HoldTheLine

  Dec 9, 2025

  $BYSI Got the hustle to make big moves, don’t sleep on this!

  Buy

• CashOverload

  Dec 9, 2025

  $BYSI Heavy inflows into this name.

  Buy

• WallStreetHex

  Dec 9, 2025

  $BYSI Breakout above resistance looks imminent.

  Buy

• WallStreetGrim

  Dec 8, 2025

  $BYSI With a focus on developing innovative therapies, this firm is dedicated to addressing significant health challenges. Their research-driven approach indicates potential for impactful breakthroughs.

  Buy

• WallStreetVandal

  Dec 8, 2025

  $BYSI Chasing trends in a crowded market is never a smart move.

  Sell

• StonkKnight

  Dec 7, 2025

  $BYSI Therapy vibes? This one's bringin' the heat to the health scene!

  Buy

• QuantAssault

  Dec 7, 2025

  $BYSI This stock is like that underdog movie where the main character surprises everyone – get ready for some serious plot twists!

  Buy

• YOLOHold

  Dec 6, 2025

  $BYSI Chillin' with some real potential, just watch it bloom.

  Buy

• HedgeKnight

  Dec 6, 2025

  $BYSI This company is like that friend who always brings snacks—beyond fantastic and definitely keeps the party going!

  Buy

• RiskProtocol

  Dec 6, 2025

  $BYSI In the biotech arena, every second counts, and breakthroughs can transform fortunes overnight. But is there enough fuel in the tank to keep this race going?

  Buy

• CryptoCobra

  Dec 5, 2025

  $BYSI If this stock were a superhero, it’d be the one with the cool gadgets and a knack for turning things around!

  Buy

• DiamondHands

  Dec 5, 2025

  $BYSI BeyondSpring is like the overachiever in class—always showing off how cool they are with innovative solutions and a sprinkle of magic!

  Buy

• TradePulse

  Dec 5, 2025

  $BYSI Navigating the healthcare field is like walking a tightrope—you never know when a sudden announcement could send shockwaves that keep you up at night. Be ready for anything!

  Sell

• DigitalDividend

  Dec 5, 2025

  $BYSI Curing cancer and challenges like a superhero. Is there a cape involved? Asking for a friend.

  Buy

• WallStreetRogue

  Dec 4, 2025

  $BYSI The biopharma world is rife with uncertainty, and every trial feels like a ticking time bomb! Can they deliver on their promises before the clock runs out?

  Sell

• GammaGrind

  Dec 4, 2025

  $BYSI Price action pointing down heavily.

  Sell

• MarketDrift

  Dec 4, 2025

  $BYSI Sentiment improving across the board.

  Buy

• YOLOTrader

  Dec 4, 2025

  $BYSI Bearish weight too strong.

  Sell

• OptionOverlord

  Dec 4, 2025

  $BYSI Springing into action like a superhero, this company is taking on some serious health challenges! Just don’t forget to stretch first!

  Buy

• StockStrider

  Dec 3, 2025

  $BYSI Sellers crushing upward attempts.

  Sell